International Conference on Parkinson’s Disease & Movement Disorders August 11-13, 2015 Frankfurt, Germany

Markus Schymalla has completed Medical School in 2011 at Philipps-University Marburg, Germany. He is now working to finish his MD thesis at the Department ofrnNeurology and is employed as a Resident at the Center of Radiooncology, Philipps-University Marburg.

REM-sleep Behavior Disorder (RBD) is a parasomnia which is characterized by dream-enacting behavior due to loss of normalrnskeletal muscle atonia during sleep. RBD can lead to a neurodegenerative disorder such as Parkinson disease, MSA or DLB inrn81% after 16 years. Therefore, an early diagnosis of RBD is important. Video-Polysomnography (V-PSG) is required to confirmrnthe diagnosis of RBD, which is obviously unsuitable for screening purposes. Studies using the SLEEP-EVAL system and the MayornSleep Questionnaire suggested a prevalence of RBD between 0.5 to 8.9%. Both questionnaires have poor or unknown specificity.rnRecently the ‘REM Sleep Behavior Disorder Screening Questionnaire’ (RBDSQ) has been validated with a sensitivity of 0.96 andrna specificity of up to 0.92 underlining its potential usefulness as a screening instrument. The objective of this research project wasrnto investigate the prevalence of RBD by the RBDSQ in non-neurological patients. Between October 2008 and October 2010 thernRBDSQ was administered to 551 subjects in the out-patient setting of GP practices and the in-patient setting of non-neurologicalrnwards. This screening revealed a prevalence of 27%, clearly exceeding previously known data. Accordingly, after performing arnV-PSG in five participants we confirmed only one case of RBD and another case with possible RBD. The present work suggestsrnthat results of the RBDSQ and probably also other questionnaires have to be interpreted with caution. Its usefulness as a screeningrninstrument needs further investigation and refinement.

Yue Erli, Tongji University, China

Objective: To observe the changes of CD4+CD25+FoxP3 and IL-2, IL-6, IL-10, TNF-α inflammatory factors in the peripheralrnblood of the early PD patients and to further explore the correlations about CD4+CD25+FoxP3 and IL-2, IL-6, IL-10, TNF-αrninflammatory factors in peripheral blood of the early PD patients whether the level of CD4+CD25+FoxP3 and IL-2, IL-6, IL-10,rnTNF-αin different years, sex, grade and depression or not is different.rnMethods: CD4+CD25+FoxP3 were measured in 15 PD patients by the direct immunofluroscent staining technique and whichrnrelated inflammatory factors were measured by ELISA and compared with 30 normal controls.rnResults: The levels of CD4+CD25+FoxP3 in PD were depressed as compared with healthy controls (p<0.01). The levels of IL-2,rnIL-6, IL-10 and TNF-α in PD were higher than healthy controls (p<0.05). Different ages, different grade, presence or absencernof depression among PD patients, peripheral blood CD4+CD25+FoxP3 and which related inflammatory factors were notrnsignificantly different (p>0.05). IL-10 was significantly different between men and women in the PD group, the female level ofrnIL-10 was higher than the male (p<0.05), CD4+CD25+FoxP3 and the rest of the inflammatory factors were not different (p>0.05),rnthe changes of CD4+CD25+FoxP3, IL-2, IL-6, IL-10 and TNF-α in peripheral blood were in no significant correlation comparedrnwith age, sex, grade and depression.rnConclusion: CD4+CD25+FoxP3 immune functional decline and imbalance of IL-2, IL-6, IL-10 and TNF-α inflammatoryrnfactor were observed in early PD patients. The cellular immune function in patients was no significant among different ages,rndifferent classification and depressive symptoms or not but the level of IL-10 exists difference between male and female groups,rnCD4+CD25+FoxP3 and IL-2, IL-6, IL-10, TNF-α may be involved in the pathogenesis of early Parkinson’s disease in thernpathophysiology and pathogenesis of PD has played a certain role.

Sahar Mohamed Kamal Shams El-Dine is currently an Associate Professor in the Department of Pharmacology at Ain Shams University, Egypt. His research interestrnincludes GABAergic and glutamergic effects of drugs acting on CNS, neurogenesis and neuroplasticity that would promote the improvement done by antidepressants andrnantipsychotics in treatment of depression and psychosis.

Background: CoQ10 is currently under investigation for the treatment of neurodegenerative disorders. Although not yetrnapproved by the FDA, the product is available from health food stores.rnAim: The aim of this work is to investigate possible beneficial effects of coenzyme Q10 administered i.p. on hippocampi ofrn12 albino rats exposed to a Parkinson model on selected hippocampal oxidative stress markers [Thiobarbituric-acid reactivernsubstance (TBARS), MDA, GSH), brain derived-neurotropic factor (BDNF) and cyclooxygenase-2 (COX-2) enzyme genernexpression].rnMethods: Thirty-six albino rats were randomly classified into 3 groups (n of each=12 rats). Group 1 includes control saline-injectedrni.p., Group 2 includes control Parkinson-induced model with i.p. injection with 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridinernwithout any anti-Parkinson’s therapy or coenzyme Q10 injection and Group 3 includes coenzyme Q10-treated Parkinson-inducedrnmodel by i.p. injection at a dose of 50 mg/kg/day for 21 days. A pilot study showed no significant (p<0.05) changes of coenzymernQ10 on the measured parameters in hippocampi in normal saline-treated non-Parkinsonian albino rats.rnResults: Coenzyme Q10 treated rats showed a significant (p<0.05) reduction in both hippocampal TBARS and MDA with arnsignificant (p<0.05) increase in its GSH. Additionally, a significant (p<0.05) increase in level of hippocampal BDNF with a downregulationrnof gene expression of COX-2 enzyme was seen.rnConclusion: Data obtained from the current study pointed to possible therapeutic effects of coenzyme Q10 in a Parkinson modelrnof albino rats. These effects included an antioxidant, a neuro regenerative and anti-inflammatory effect of the coenzyme on thernhippocampi homogenates of such animal model.